ProCP-2

ProCP-2 is a recombinant human pro-carboxypeptidase B2 (pro-CPB2), also known as pro-thrombin-activatable fibrinolysis inhibitor (pro-TAFI), currently under development by Prothix. As a zymogen, ProCP-2 is activated by the thrombin-thrombomodulin complex into TAFIa, a basic carboxypeptidase that regulates both the coagulation and complement systems. TAFIa stabilizes blood clots by removing C-terminal lysine residues from fibrin, which prevents the binding and activation of plasminogen and tissue plasminogen activator (tPA), thereby slowing fibrinolysis. Beyond its role in hemostasis, TAFIa exerts potent anti-inflammatory effects by enzymatically inactivating pro-inflammatory peptides, including the complement anaphylatoxins C3a and C5a, bradykinin, and osteopontin. ProCP-2 is being evaluated in clinical trials for its potential to treat acute inflammatory and thrombotic conditions, such as sepsis, where dysregulated fibrinolysis and 'complement storm' contribute to organ failure and mortality.

Other names

recombinant human pro-carboxypeptidase B2rhPro-CPB2rhPro-CPB-2rhPro-CPB 2pro-TAFIpro-thrombin-activatable fibrinolysis inhibitor